Description

Balchem Corporation: Will Its Increased Focus On Sustainable Solutions Up Their Game?

Balchem reported strong financial performance for the fourth quarter and full year 2024, demonstrating revenue growth across all three of its business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Consolidated fourth-quarter sales increased by 4.9% year-over-year to $240 million, marking a record quarter for the company. Gross margin expanded by 320 basis points to 36%, driven by a favorable portfolio mix, contributing to an adjusted EBITDA increase of 13.4% to $63 million. The company achieved a 23.8% rise in GAAP earnings from operations and a 26% increase in net income, reaching $34 million. Diluted net earnings per share on a GAAP basis rose 25.6% to $1.03, while adjusted earnings per share increased 18.9% to $1.13. Free cash flow generation remained strong at $52 million for the quarter, allowing Balchem to continue reducing debt, ending the quarter with a net debt position of $140 million and a leverage ratio of 0.6x.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!